^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GCN2 activator

    Related drugs:
    Apply
    A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101) (NCT05226507)
    Phase 1
    Nuvectis Pharma, Inc.
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/31/2021
    Primary completion :
    05/01/2025
    Completion :
    12/01/2025
    ARID1A • BRCA
    |
    ARID1A mutation • BRCA mutation
    |
    NXP800
    A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma (MK-6482-030) (NCT06234605)
    Phase 1
    HiberCell, Inc.
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    04/29/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2027
    VHL
    |
    VHL mutation
    |
    Welireg (belzutifan) • HC-7366